Sign In

Use the Qualified Clinical Data Registry (QCDR) to complete Merit-Based Incentive Payment System reporting.

Report on evidence-based quality measures and receive performance scores via the Quality Oncology Practice Initiative (QOPI®).

Oncology Practice Insider

ASCO’s Oncology Practice Insider provides the latest news, information, and educational tools to assist with the successful management of oncology practice and the delivery of high quality patient care. OPI offers updates on ASCO programs, services, and cancer-related health policy, Medicare news, and billing and coding best practices. To sign up for the biweekly Oncology Practice Insider newsletter, please complete this form.

Date
ASCO published the following new guidelines:
The American Society of Clinical Oncology’s latest policy brief provides an overview of the issues complicating health care price transparency, the society’s concerns about how the lack of price transparency in the health care system is impacting people with cancer, and how drug manufacturers, pharmacy benefit managers, and other stakeholders can be more transparent in a way that is meaningful for patients and providers. Read the bri
On January 27, the Centers for Medicare & Medicaid Services (CMS) announced that it is expanding its coverage of next generation sequencing (NGS) for use as a diagnostic tool for certain patients with cancer. Specifically, CMS will now cover FDA-approved or cleared laboratory diagnostic tests detecting germline mutations for patients with breast and ovarian cancer, or somatic mutations for patients with advanced cancer. This National Coverage Decision (NCD) expands on CMS’ previous decision to cover NGS laboratory diagnostic tests for certain patients with advanced cancer.
In January, PracticeNET added three new practices, increasing its total participation to 57 practices.  One newcomer was Munson Healthcare’s Cowell Family Cancer Center out of Traverse City, Michigan.  Welcome to our newest members!
The American Society of Clinical Oncology (ASCO) released a position statement, “Block Grants in Medicaid & Their Impact on Cancer Care,” that urges policymakers not to enact, apply for, or advance any proposals to establish block grants for Medicaid programs. 
The American Society of Clinical Oncology (ASCO) recently submitted its Patient-Centered Oncology Payment model for consideration by the Physician-Focused Payment Model Technical Advisory Committee (PTAC) as a way to improve the quality of cancer care, while lowering costs.   “Participation by the Medicare and Medicaid programs would advance this model in its intent to establish communities of providers and payers working together to improve cancer care delivery.” said ASCO in its submission letter. 
ASCO published the following new guidelines:
On January 23, 2020, the Food and Drug Administration granted accelerated approval to tazemetostat (TAZVERIK™, Epizyme, Inc.) for adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. Read more.